Researchers at the University of Cambridge report that low levels of placental protein isthmin-2 at 12 weeks gestation may predict risk of pre-eclampsia and fetal growth restriction, according to a study in Nature Medicine.
A study found that faster blood processing could double the detection of gestational diabetes, reducing complications for mothers and babies.
Labs should consider self-reported race when screening for open neural tube defects to improve prenatal care equity for Black individuals.
Devyser Compact is a rapid genetic test for prenatal chromosome testing and is approved under the new more comprehensive regulation.
Read More
Juno Diagnostics has announced the launch of Juno Hazel, a non-invasive prenatal screening (NIPS) solution.
Read More
Sera Prognostics’ blood-based test offers individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
Read More
Cedars-Sinai investigators have found that a specific imbalance of two placental proteins could predict preeclampsia risk.
Read More
Diagnostic screening for Down’s Syndrome during pregnancy was difficult until the development of an NIPT fetal fraction test.
Read More
Researchers may have identified an effective way of detecting gestational diabetes mellitus (GDM) earlier in pregnancy.
Read More
Sera Prognostics, a company focused on curbing preterm birth risks, demonstrated data on the health and economic benefits of its PreTRM test.
Read More
The FDA is warning the public of the risk of false results, inappropriate use, and inappropriate interpretation of results with NIPS tests.
Read More
Sema4 and Mount Sinai collaborated on two studies that demonstrate how machine learning can be used to improve postpartum hemorrhage risk prediction.
Read More
Researchers have developed a testing device that may help advance diagnosis and treatment of preterm birth.
Read More
Veritas has created a new prenatal diagnostic test that can help identify fetal anomalies in at-risk pregnancies.
Read More
Researchers have identified biological markers that could improve blood tests of pregnant women to detect risks of pregnancy complications earlier.
Read More
BioFluidica, a privately held biotechnology company, plans to commercialize its LiquidScan Automated Liquid Biopsy System.Â
Read More
Sema4 Elements, a portfolio of information-driven genomic reproductive health solutions that enable providers to treat patients holistically, has launched.
Read More
Half of pregnant women who had a simple blood test to check their iron stores had low iron levels; one in four had severe iron deficiency.
Read More